Here are the DEF 14A proxy statements from Vanda Pharmaceuticals Inc. (VNDA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow VNDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VNDA filings page.
Vanda Pharmaceuticals is asking stockholders to vote at its virtual 2026 annual meeting on June 4, 2026. Proposals include electing three Class II directors through 2029, ratifying PricewaterhouseCoopers as auditor, an advisory vote on executive pay and increasing shares under the 2016 Equity Incentive Plan.
The record date is April 17, 2026, with 60,135,062 common shares outstanding. The proxy highlights 2025 total revenue of $216.1 million, including Fanapt, HETLIOZ and PONVORY sales, year-end cash and securities of $263.8 million and a net loss of $220.5 million after a large non-cash tax valuation allowance. It also outlines multiple late-stage clinical programs, an FDA approval for tradipitant in motion sickness and a BLA filing for imsidolimab in generalized pustular psoriasis.